Cells have evolved a complex network of biochemical pathways, collectively known as the
DNA damage response (DDR), to prevent detrimental mutations from being passed on to …

Replication stress is a major cause of genomic instability and a crucial vulnerability of
cancer cells. This vulnerability can be therapeutically targeted by inhibiting kinases that …

The molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and
progression are being increasingly defined. The TRACERx Renal studies and others that …

Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …

In vertebrate cells, the DNA damage response is controlled by three related kinases: ATM,
ATR, and DNA-PK. It has been 20 years since the cloning of ATR, the last of the three to be …

The genetic concept of synthetic lethality has now been validated clinically through the
demonstrated efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of …

Predictive biomarkers of response are essential to effectively guide targeted cancer
treatment. Ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) have been shown …

Oncogene activation disturbs cellular processes and accommodates a complex landscape
of changes in the genome that contribute to genomic instability, which accelerates mutation …

Hematologic malignancies include various diseases that develop from hematopoietic stem
cells of bone marrow or lymphatic organs. Currently, conventional DNA-damage-based …

Resistance to chemo-and radiotherapy is a common event among cancer patients and a
reason why new cancer therapies and therapeutic strategies need to be in continuous …